Congenital Heart Disease (CHD) refers to a range of structural and functional heart abnormalities present at birth. The cardiology field categorizes these defects based on their severity, anatomical locations, and physiological impact. CHD affects the cardiac chambers, valves, septum, or great vessels, often necessitating multidisciplinary care that includes pediatric cardiologists, cardiac surgeons, and specialized nurses. Treatment modalities range from pharmaceutical management to interventional catheterization and cardiac surgery. Advances in diagnostics, such as echocardiography, magnetic resonance imaging (MRI), and genetic testing, have enhanced early detection and personalized treatment planning. Ongoing research is focused on understanding the complex etiology of congenital heart defects, involving genetic and environmental factors, and on improving patient outcomes through innovative surgical techniques and postoperative care strategies.
Within the CHD market, several prominent companies focus on therapeutic solutions and medical devices tailored for managing and correcting congenital heart anomalies. Medtronic, Abbott Laboratories, and Boston Scientific are notable for providing advanced medical devices, including stents and occlusion devices. St. Jude Medical, acquired by Abbott Laboratories, also plays a key role in the market. Edwards Lifesciences is known for its heart valves and repair products, while Philips offers sophisticated imaging technologies critical for the diagnosis and treatment planning of CHD. These companies contribute to the evolving landscape of care for patients with congenital heart diseases through their continued innovation and dedication to improving cardiac health. Show Less Read more
